Company Description
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart.
In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer’s disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent.
It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
| Country | United States |
| Founded | 1956 |
| IPO Date | Jun 25, 2015 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 808 |
| CEO | Brian Markison |
Contact Details
Address: 201 Burlington Road, South Building Bedford, Massachusetts 01730 United States | |
| Phone | 978 671 8001 |
| Website | lantheus.com |
Stock Details
| Ticker Symbol | LNTH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001521036 |
| CUSIP Number | 516544103 |
| ISIN Number | US5165441032 |
| Employer ID | 35-2318913 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Brian A. Markison | Chief Executive Officer and Director |
| Paul M. Blanchfield | President |
| Robert J. Marshall Jr., CFA | Chief Financial Officer and Treasurer |
| Dr. Jean-Claude Provost M.D. | Chief Science Officer |
| Daniel M. Niedzwiecki | Chief Administrative Officer, General Counsel and Corporate Secretary |
| Kimberly Brown | Chief Accounting Officer |
| Dorothy Barr | Senior Vice President of Manufacturing and Technical Operations |
| Lee Anne Howe | Chief Information Officer |
| Mark Richard Kinarney | Senior Director of Investor Relations |
| Linda S. Lennox | Vice President of Corporate Communications and Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2025 | ARS | Filing |
| Mar 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 21, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 17, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Feb 28, 2025 | 144 | Filing |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |